Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A M Lincoff

Showing results (111-120 of 116) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 116 results.
European Heart Journal|February 27, 2004
Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromesM T Roe, K W Mahaffey, R Kilaru, et al.
Journal of the American College of Cardiology|June 17, 1998
Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary ThrombosisJ S Mandak, J C Blankenship, L H Gardner, et al.
The American Journal of Cardiology|April 24, 1999
Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin TherapyJ H Alexander, R A Harrington, R H Tuttle, et al.
Circulation|May 31, 2001
Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter studyS R Steinhubl, J D Talley, G A Braden, et al.
Journal of Thrombosis and Haemostasis : JTH|March 6, 2004
Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI PilotJ H Alexander, C K Dyke, H Yang, et al.
Circulation|November 1, 1996
Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trialS P Schulman, P J Goldschmidt-Clermont, E J Topol, et al.
Pageof 12

Showing results (111-120 of 116) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 116 results.
European Heart Journal|February 27, 2004
Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromesM T Roe, K W Mahaffey, R Kilaru, et al.
Journal of the American College of Cardiology|June 17, 1998
Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary ThrombosisJ S Mandak, J C Blankenship, L H Gardner, et al.
The American Journal of Cardiology|April 24, 1999
Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin TherapyJ H Alexander, R A Harrington, R H Tuttle, et al.
Circulation|May 31, 2001
Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter studyS R Steinhubl, J D Talley, G A Braden, et al.
Journal of Thrombosis and Haemostasis : JTH|March 6, 2004
Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI PilotJ H Alexander, C K Dyke, H Yang, et al.
Circulation|November 1, 1996
Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trialS P Schulman, P J Goldschmidt-Clermont, E J Topol, et al.
Pageof 12